-
1
-
-
79958274304
-
The treatment of cognitive impairment in schizophrenia
-
Goff DC, Hill M, Barch D,. The treatment of cognitive impairment in schizophrenia. Pharmacology, Biochemistry & Behavior 2011; 99: 245-53.
-
(2011)
Pharmacology, Biochemistry & Behavior
, vol.99
, pp. 245-253
-
-
Goff, D.C.1
Hill, M.2
Barch, D.3
-
2
-
-
33750625280
-
Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review
-
Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5-25.
-
(2006)
Schizophr Res
, vol.88
, pp. 5-25
-
-
Murphy, B.P.1
Chung, Y.C.2
Park, T.W.3
-
3
-
-
68449086236
-
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
-
International Schizophrenia Consortium
-
International Schizophrenia Consortium, Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-52.
-
(2009)
Nature
, vol.460
, pp. 748-752
-
-
Purcell, S.M.1
Wray, N.R.2
-
4
-
-
54149094913
-
Genetic research in schizophrenia: New tools and future perspectives
-
Bertram L,. Genetic research in schizophrenia: new tools and future perspectives. Schizophr Bull 2008; 34: 806-12.
-
(2008)
Schizophr Bull
, vol.34
, pp. 806-812
-
-
Bertram, L.1
-
5
-
-
84867743306
-
Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users
-
Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012; 72: 811-6.
-
(2012)
Biol Psychiatry
, vol.72
, pp. 811-816
-
-
Di Forti, M.1
Iyegbe, C.2
Sallis, H.3
-
6
-
-
0028316414
-
Cannabis abuse and the course of recent-onset schizophrenic disorders
-
Linszen DH, Dingemans PM, Lenior ME,. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9.
-
(1994)
Arch Gen Psychiatry
, vol.51
, pp. 273-279
-
-
Linszen, D.H.1
Dingemans, P.M.2
Lenior, M.E.3
-
7
-
-
84555220553
-
Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume
-
Mondelli V, Cattaneo A, Belvederi Murri M, et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry 2011; 72: 1677-84.
-
(2011)
J Clin Psychiatry
, vol.72
, pp. 1677-1684
-
-
Mondelli, V.1
Cattaneo, A.2
Belvederi Murri, M.3
-
8
-
-
68049121851
-
The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients
-
Zhang XY, Chen da C, Xiu MH, et al. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res 2009; 113: 151-7.
-
(2009)
Schizophr Res
, vol.113
, pp. 151-157
-
-
Zhang, X.Y.1
Chen Da, C.2
Xiu, M.H.3
-
9
-
-
84860835844
-
Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes
-
Martinez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012; 137: 66-72.
-
(2012)
Schizophr Res
, vol.137
, pp. 66-72
-
-
Martinez-Cengotitabengoa, M.1
Mac-Dowell, K.S.2
Leza, J.C.3
-
10
-
-
78651312636
-
Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: An activation likelihood estimation meta-analysis of illness progression
-
Chan RC, Di X, McAlonan GM, et al. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr Bull 2011; 37: 177-88.
-
(2011)
Schizophr Bull
, vol.37
, pp. 177-188
-
-
Chan, R.C.1
Di, X.2
McAlonan, G.M.3
-
12
-
-
0033399541
-
Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies
-
Laruelle M, Abi-Dargham A,. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13: 358-71.
-
(1999)
J Psychopharmacol
, vol.13
, pp. 358-371
-
-
Laruelle, M.1
Abi-Dargham, A.2
-
13
-
-
0034843738
-
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
-
Goff DC, Coyle JT,. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77.
-
(2001)
Am J Psychiatry
, vol.158
, pp. 1367-1377
-
-
Goff, D.C.1
Coyle, J.T.2
-
14
-
-
33845794324
-
Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks
-
Bartos M, Vida I, Jonas P,. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nature Rev Neurosci 2007; 8: 45-56.
-
(2007)
Nature Rev Neurosci
, vol.8
, pp. 45-56
-
-
Bartos, M.1
Vida, I.2
Jonas, P.3
-
15
-
-
24344441586
-
Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review
-
Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-83.
-
(2005)
Arch Gen Psychiatry
, vol.62
, pp. 975-983
-
-
Marshall, M.1
Lewis, S.2
Lockwood, A.3
-
16
-
-
65649137337
-
Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders
-
Dorph-Petersen KA, Caric D, Saghafi R, et al. Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders. Acta Neuropathol 2009; 117: 369-84.
-
(2009)
Acta Neuropathol
, vol.117
, pp. 369-384
-
-
Dorph-Petersen, K.A.1
Caric, D.2
Saghafi, R.3
-
17
-
-
27744569450
-
The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys
-
Dorph-Petersen KA, Pierri JN, Perel JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30: 1649-61.
-
(2005)
Neuropsychopharmacology
, vol.30
, pp. 1649-1661
-
-
Dorph-Petersen, K.A.1
Pierri, J.N.2
Perel, J.M.3
-
18
-
-
79955474356
-
Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and postmortem confirmation
-
Vernon AC, Natesan S, Modo M, et al. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2011; 69: 936-44.
-
(2011)
Biol Psychiatry
, vol.69
, pp. 936-944
-
-
Vernon, A.C.1
Natesan, S.2
Modo, M.3
-
19
-
-
0034678029
-
Reversal of working memory deficits by short-term dopamine D1 receptor stimulation
-
Castner SA, Williams GV, Goldman-Rakic PS,. Reversal of working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000; 287: 2020-2.
-
(2000)
Science
, vol.287
, pp. 2020-2022
-
-
Castner, S.A.1
Williams, G.V.2
Goldman-Rakic, P.S.3
-
20
-
-
3543093977
-
Serologic evidence of prenatal influenza in the etiology of schizophrenia
-
Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61: 774-80.
-
(2004)
Arch Gen Psychiatry
, vol.61
, pp. 774-780
-
-
Brown, A.S.1
Begg, M.D.2
Gravenstein, S.3
-
21
-
-
36049009089
-
Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study
-
Byrne M, Agerbo E, Bennedsen B, et al. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 2007; 97: 51-9.
-
(2007)
Schizophr Res
, vol.97
, pp. 51-59
-
-
Byrne, M.1
Agerbo, E.2
Bennedsen, B.3
-
22
-
-
2442593823
-
Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring
-
Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004; 161: 889-95.
-
(2004)
Am J Psychiatry
, vol.161
, pp. 889-895
-
-
Brown, A.S.1
Hooton, J.2
Schaefer, C.A.3
-
23
-
-
73949137920
-
Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: Cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii
-
Carter CJ,. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr Bull 2009; 35: 1163-82.
-
(2009)
Schizophr Bull
, vol.35
, pp. 1163-1182
-
-
Carter, C.J.1
-
24
-
-
0033588276
-
Evidence for activation of microglia in patients with psychiatric illnesses
-
Bayer TA, Buslei R, Havas L, et al. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-8.
-
(1999)
Neurosci Lett
, vol.271
, pp. 126-128
-
-
Bayer, T.A.1
Buslei, R.2
Havas, L.3
-
25
-
-
0033983020
-
Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics
-
Radewicz K, Garey LJ, Gentleman SM, et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exper Neurol 2000; 59: 137-50.
-
(2000)
J Neuropathol Exper Neurol
, vol.59
, pp. 137-150
-
-
Radewicz, K.1
Garey, L.J.2
Gentleman, S.M.3
-
26
-
-
53249144430
-
Microglia activation in recent-onset schizophrenia: A quantitative (R)-[11C]PK11195 positron emission tomography study
-
van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-2.
-
(2008)
Biol Psychiatry
, vol.64
, pp. 820-822
-
-
Van Berckel, B.N.1
Bossong, M.G.2
Boellaard, R.3
-
27
-
-
70350724581
-
Neuroinflammation in schizophrenia-related psychosis: A PET study
-
Doorduin J, de Vries EF, Willemsen AT, et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-7.
-
(2009)
J Nucl Med
, vol.50
, pp. 1801-1807
-
-
Doorduin, J.1
De Vries, E.F.2
Willemsen, A.T.3
-
28
-
-
61849179511
-
Therapeutic signposts: Using biomarkers to guide better treatment of schizophrenia and other psychotic disorders
-
Banati R, Hickie IB,. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Med J Aust 2009; 190 (Suppl. 4): S26-32.
-
(2009)
Med J Aust
, vol.190
, Issue.SUPPL. 4
-
-
Banati, R.1
Hickie, I.B.2
-
29
-
-
80052853015
-
Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects
-
Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-71.
-
(2011)
Biol Psychiatry
, vol.70
, pp. 663-671
-
-
Miller, B.J.1
Buckley, P.2
Seabolt, W.3
-
30
-
-
67749114055
-
Immune involvement in schizophrenia and autism: Etiology, pathology and animal models
-
Patterson PH,. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009; 204: 313-21.
-
(2009)
Behav Brain Res
, vol.204
, pp. 313-321
-
-
Patterson, P.H.1
-
31
-
-
48249117121
-
Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring
-
Makinodan M, Tatsumi K, Manabe T, et al. Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J Neurosci Res 2008; 86: 2190-200.
-
(2008)
J Neurosci Res
, vol.86
, pp. 2190-2200
-
-
Makinodan, M.1
Tatsumi, K.2
Manabe, T.3
-
32
-
-
84861947641
-
Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring
-
Forrest CM, Khalil OS, Pisar M, et al. Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Mol Brain 2012; 5: 22.
-
(2012)
Mol Brain
, vol.5
, pp. 22
-
-
Forrest, C.M.1
Khalil, O.S.2
Pisar, M.3
-
33
-
-
80051789320
-
Microglial activation in a neuroinflammational animal model of schizophrenia - A pilot study
-
Juckel G, Manitz MP, Brune M, et al. Microglial activation in a neuroinflammational animal model of schizophrenia-a pilot study. Schizophr Res 2011; 131: 96-100.
-
(2011)
Schizophr Res
, vol.131
, pp. 96-100
-
-
Juckel, G.1
Manitz, M.P.2
Brune, M.3
-
34
-
-
70350721661
-
Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia
-
Piontkewitz Y, Assaf Y, Weiner I,. Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry 2009; 66: 1038-46.
-
(2009)
Biol Psychiatry
, vol.66
, pp. 1038-1046
-
-
Piontkewitz, Y.1
Assaf, Y.2
Weiner, I.3
-
35
-
-
34249335327
-
C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia
-
Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007; 93: 261-5.
-
(2007)
Schizophr Res
, vol.93
, pp. 261-265
-
-
Dickerson, F.1
Stallings, C.2
Origoni, A.3
-
36
-
-
33846261538
-
Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia
-
Fan X, Pristach C, Liu EY, et al. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007; 149: 267-71.
-
(2007)
Psychiatry Res
, vol.149
, pp. 267-271
-
-
Fan, X.1
Pristach, C.2
Liu, E.Y.3
-
37
-
-
83655163937
-
C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia
-
Fawzi MH, Fawzi MM, Fawzi MM, et al. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 2011; 190: 91-7.
-
(2011)
Psychiatry Res
, vol.190
, pp. 91-97
-
-
Fawzi, M.H.1
Fawzi, M.M.2
Fawzi, M.M.3
-
38
-
-
80052437053
-
Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: A longitudinal study
-
Prasad KM, Eack SM, Goradia D, et al. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. Am J Psychiatry 2011; 168: 822-30.
-
(2011)
Am J Psychiatry
, vol.168
, pp. 822-830
-
-
Prasad, K.M.1
Eack, S.M.2
Goradia, D.3
-
39
-
-
79955474674
-
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample
-
Yolken RH, Torrey EF, Lieberman JA, et al. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res 2011; 128: 61-5.
-
(2011)
Schizophr Res
, vol.128
, pp. 61-65
-
-
Yolken, R.H.1
Torrey, E.F.2
Lieberman, J.A.3
-
40
-
-
67650652986
-
Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?
-
Behrens MM, Sejnowski TJ,. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology 2009; 57: 193-200.
-
(2009)
Neuropharmacology
, vol.57
, pp. 193-200
-
-
Behrens, M.M.1
Sejnowski, T.J.2
-
41
-
-
67649840212
-
The development of neural synchrony reflects late maturation and restructuring of functional networks in humans
-
Uhlhaas PJ, Roux F, Singer W, et al. The development of neural synchrony reflects late maturation and restructuring of functional networks in humans. Proc Natl Acad Sci USA 2009; 106: 9866-71.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 9866-9871
-
-
Uhlhaas, P.J.1
Roux, F.2
Singer, W.3
-
42
-
-
0344628603
-
Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: Parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity
-
Sirota P, Gavrieli R, Wolach B,. Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry Res 2003; 121: 123-32.
-
(2003)
Psychiatry Res
, vol.121
, pp. 123-132
-
-
Sirota, P.1
Gavrieli, R.2
Wolach, B.3
-
43
-
-
33845671189
-
Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo
-
Weiss TW, Samson AL, Niego B, et al. Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB Journal 2006; 20: 2369-71.
-
(2006)
FASEB Journal
, vol.20
, pp. 2369-2371
-
-
Weiss, T.W.1
Samson, A.L.2
Niego, B.3
-
44
-
-
47249164327
-
Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder
-
Beneyto M, Meador-Woodruff JH,. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008; 33: 2175-86.
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 2175-2186
-
-
Beneyto, M.1
Meador-Woodruff, J.H.2
-
45
-
-
70349774217
-
Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats
-
Galic MA, Riazi K, Henderson AK, et al. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 2009; 36: 343-51.
-
(2009)
Neurobiol Dis
, vol.36
, pp. 343-351
-
-
Galic, M.A.1
Riazi, K.2
Henderson, A.K.3
-
46
-
-
16844382943
-
BDNF in schizophrenia, depression and corresponding animal models
-
Angelucci F, Brene S, Mathe AA,. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005; 10: 345-52.
-
(2005)
Mol Psychiatry
, vol.10
, pp. 345-352
-
-
Angelucci, F.1
Brene, S.2
Mathe, A.A.3
-
47
-
-
77954421126
-
The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus
-
Ninan I, Bath KG, Dagar K, et al. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J Neurosci 2010; 30: 8866-70.
-
(2010)
J Neurosci
, vol.30
, pp. 8866-8870
-
-
Ninan, I.1
Bath, K.G.2
Dagar, K.3
-
48
-
-
78650799875
-
Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression
-
Kanellopoulos D, Gunning FM, Morimoto SS, et al. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry 2011; 19: 13-22.
-
(2011)
Am J Geriatr Psychiatry
, vol.19
, pp. 13-22
-
-
Kanellopoulos, D.1
Gunning, F.M.2
Morimoto, S.S.3
-
50
-
-
38449085832
-
Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia
-
Ho BC, Andreasen NC, Dawson JD, et al. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry 2007; 164: 1890-9.
-
(2007)
Am J Psychiatry
, vol.164
, pp. 1890-1899
-
-
Ho, B.C.1
Andreasen, N.C.2
Dawson, J.D.3
-
51
-
-
77950598371
-
Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action
-
Freyberg Z, Ferrando SJ, Javitch JA,. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010; 167: 388-96.
-
(2010)
Am J Psychiatry
, vol.167
, pp. 388-396
-
-
Freyberg, Z.1
Ferrando, S.J.2
Javitch, J.A.3
-
52
-
-
78649906486
-
Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia
-
Balu DT, Coyle JT,. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 2012; 35: 848-70.
-
(2012)
Neurosci Biobehav Rev
, vol.35
, pp. 848-870
-
-
Balu, D.T.1
Coyle, J.T.2
-
54
-
-
84863872722
-
Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: A randomized controlled trial
-
Kiecolt-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain, Behavior and Immunity 2012; 26: 988-95.
-
(2012)
Brain, Behavior and Immunity
, vol.26
, pp. 988-995
-
-
Kiecolt-Glaser, J.K.1
Belury, M.A.2
Andridge, R.3
-
55
-
-
76149102249
-
Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial
-
Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-54.
-
(2010)
Arch Gen Psychiatry
, vol.67
, pp. 146-154
-
-
Amminger, G.P.1
Schafer, M.R.2
Papageorgiou, K.3
-
56
-
-
84857885522
-
Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies
-
Fusar-Poli P, Berger G,. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 2012; 32: 179-85.
-
(2012)
J Clin Psychopharmacol
, vol.32
, pp. 179-185
-
-
Fusar-Poli, P.1
Berger, G.2
-
57
-
-
33846620518
-
Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
-
Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-85.
-
(2007)
Schizophr Res
, vol.90
, pp. 179-185
-
-
Akhondzadeh, S.1
Tabatabaee, M.2
Amini, H.3
-
58
-
-
77955050321
-
Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
-
Muller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010; 121: 118-24.
-
(2010)
Schizophr Res
, vol.121
, pp. 118-124
-
-
Muller, N.1
Krause, D.2
Dehning, S.3
-
59
-
-
77952641170
-
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial
-
Laan W, Grobbee DE, Selten JP, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-7.
-
(2010)
J Clin Psychiatry
, vol.71
, pp. 520-527
-
-
Laan, W.1
Grobbee, D.E.2
Selten, J.P.3
-
60
-
-
84860544826
-
Nonsteroidal anti-inflammatory drugs in schizophrenia: Ready for practice or a good start? A meta-analysis
-
Sommer IE, de Witte L, Begemann M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012; 73: 414-9.
-
(2012)
J Clin Psychiatry
, vol.73
, pp. 414-419
-
-
Sommer, I.E.1
De Witte, L.2
Begemann, M.3
-
61
-
-
84864999825
-
Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment
-
Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-93.
-
(2012)
J Psychopharmacol
, vol.26
, pp. 1185-1193
-
-
Chaudhry, I.B.1
Hallak, J.2
Husain, N.3
-
62
-
-
79851486421
-
11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats
-
Converse AK, Larsen EC, Engle JW, et al. 11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. J Nucl Med 2011; 52: 257-62.
-
(2011)
J Nucl Med
, vol.52
, pp. 257-262
-
-
Converse, A.K.1
Larsen, E.C.2
Engle, J.W.3
-
63
-
-
0035871840
-
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
-
Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001; 21: 2580-8.
-
(2001)
J Neurosci
, vol.21
, pp. 2580-2588
-
-
Tikka, T.1
Fiebich, B.L.2
Goldsteins, G.3
-
64
-
-
84864999825
-
Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment
-
Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-93.
-
(2012)
J Psychopharmacol
, vol.26
, pp. 1185-1193
-
-
Chaudhry, I.B.1
Hallak, J.2
Husain, N.3
-
65
-
-
77649112679
-
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
-
Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-49.
-
(2010)
J Clin Psychiatry
, vol.71
, pp. 138-149
-
-
Levkovitz, Y.1
Mendlovich, S.2
Riwkes, S.3
-
66
-
-
67650932879
-
Redox dysregulation, neurodevelopment, and schizophrenia
-
Do KQ, Cabungcal JH, Frank A, et al. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009; 19: 220-30.
-
(2009)
Curr Opin Neurobiol
, vol.19
, pp. 220-230
-
-
Do, K.Q.1
Cabungcal, J.H.2
Frank, A.3
-
67
-
-
43649090465
-
Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine
-
Baker DA, Madayag A, Kristiansen LV, et al. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 2008; 33: 1760-72.
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 1760-1772
-
-
Baker, D.A.1
Madayag, A.2
Kristiansen, L.V.3
-
68
-
-
48749112603
-
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
-
Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64: 361-8.
-
(2008)
Biol Psychiatry
, vol.64
, pp. 361-368
-
-
Berk, M.1
Copolov, D.2
Dean, O.3
-
69
-
-
47249165587
-
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
-
Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008; 33: 2187-99.
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 2187-2199
-
-
Lavoie, S.1
Murray, M.M.2
Deppen, P.3
-
70
-
-
84857482073
-
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: A double-blind, randomized, placebo-controlled trial
-
Carmeli C, Knyazeva MG, Cuenod M, et al. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PloS One 2012; 7: e29341.
-
(2012)
PloS One
, vol.7
-
-
Carmeli, C.1
Knyazeva, M.G.2
Cuenod, M.3
-
71
-
-
0034671366
-
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
-
Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
-
(2000)
J Neurosci
, vol.20
, pp. 9104-9110
-
-
Malberg, J.E.1
Eisch, A.J.2
Nestler, E.J.3
-
72
-
-
0042528720
-
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
-
Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
-
(2003)
Science
, vol.301
, pp. 805-809
-
-
Santarelli, L.1
Saxe, M.2
Gross, C.3
-
73
-
-
36349027843
-
Is it time to reassess the BDNF hypothesis of depression?
-
Groves JO,. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007; 12: 1079-88.
-
(2007)
Mol Psychiatry
, vol.12
, pp. 1079-1088
-
-
Groves, J.O.1
-
74
-
-
70349118076
-
Antidepressants increase neural progenitor cells in the human hippocampus
-
Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009; 34: 2376-89.
-
(2009)
Neuropsychopharmacology
, vol.34
, pp. 2376-2389
-
-
Boldrini, M.1
Underwood, M.D.2
Hen, R.3
-
75
-
-
65649125633
-
Neurogenesis-dependent and independent effects of fluoxetine in an animal model of anxiety/depression
-
David DJ, Samuels BA, Rainer Q, et al. Neurogenesis-dependent and independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009; 62: 479-93.
-
(2009)
Neuron
, vol.62
, pp. 479-493
-
-
David, D.J.1
Samuels, B.A.2
Rainer, Q.3
-
76
-
-
0034907671
-
BDNF mRNA expression in rat hippocampus and prefrontal cortex: Effects of neonatal ventral hippocampal damage and antipsychotic drugs
-
Lipska BK, Khaing ZZ, Weickert CS, et al. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001; 14: 135-44.
-
(2001)
Eur J Neurosci
, vol.14
, pp. 135-144
-
-
Lipska, B.K.1
Khaing, Z.Z.2
Weickert, C.S.3
-
77
-
-
32044441209
-
Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus
-
Pillai A, Terry A, Mahadik S,. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006; 82: 95-106.
-
(2006)
Schizophr Res
, vol.82
, pp. 95-106
-
-
Pillai, A.1
Terry, A.2
Mahadik, S.3
-
78
-
-
0036839413
-
Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration
-
Chlan-Fourney J, Ashe P, Nylen K, et al. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002; 954: 11-20.
-
(2002)
Brain Res
, vol.954
, pp. 11-20
-
-
Chlan-Fourney, J.1
Ashe, P.2
Nylen, K.3
-
79
-
-
84858338665
-
BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity
-
Bath KG, Jing DQ, Dincheva I, et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 2012; 37: 1297-304.
-
(2012)
Neuropsychopharmacology
, vol.37
, pp. 1297-1304
-
-
Bath, K.G.1
Jing, D.Q.2
Dincheva, I.3
-
80
-
-
77956864079
-
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis
-
Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010; 197: 174-9.
-
(2010)
Br J Psychiatry
, vol.197
, pp. 174-179
-
-
Singh, S.P.1
Singh, V.2
Kar, N.3
-
81
-
-
0028914983
-
A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia
-
Goff D, Midha K, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117: 417-23.
-
(1995)
Psychopharmacology
, vol.117
, pp. 417-423
-
-
Goff, D.1
Midha, K.2
Sarid-Segal, O.3
-
82
-
-
34247494128
-
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents
-
Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68: 546-57.
-
(2007)
J Clin Psychiatry
, vol.68
, pp. 546-557
-
-
Cornblatt, B.A.1
Lencz, T.2
Smith, C.W.3
-
84
-
-
76149112275
-
Hippocampal plasticity in response to exercise in schizophrenia
-
Pajonk FG, Wobrock T, Gruber O, et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 2010; 67: 133-43.
-
(2010)
Arch Gen Psychiatry
, vol.67
, pp. 133-143
-
-
Pajonk, F.G.1
Wobrock, T.2
Gruber, O.3
-
85
-
-
68949188168
-
Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?
-
Vinogradov S, Fisher M, Holland C, et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009; 66: 549-53.
-
(2009)
Biol Psychiatry
, vol.66
, pp. 549-553
-
-
Vinogradov, S.1
Fisher, M.2
Holland, C.3
-
86
-
-
0030915272
-
Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor
-
Lipton SA, Kim W-K, Choi Y-B, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Neurobiology 1997; 94: 5923-8.
-
(1997)
Neurobiology
, vol.94
, pp. 5923-5928
-
-
Lipton, S.A.1
Kim, W.-K.2
Choi, Y.-B.3
-
87
-
-
0034666267
-
Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity
-
Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-6.
-
(2000)
J Neurosci
, vol.20
, pp. 6920-6926
-
-
Kruman, I.I.1
Culmsee, C.2
Chan, S.L.3
-
89
-
-
0032527574
-
Schizophrenia and impaired homocysteine metabolism: A possible association
-
Susser E, Brown A, Klonowski E, et al. Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 1998; 44: 141-3.
-
(1998)
Biol Psychiatry
, vol.44
, pp. 141-143
-
-
Susser, E.1
Brown, A.2
Klonowski, E.3
-
91
-
-
76749133096
-
Influence of maternal MTHFR A1298C polymorphism on the risk in offspring of schizophrenia
-
Zhang C, Xie B, Fang Y, et al. Influence of maternal MTHFR A1298C polymorphism on the risk in offspring of schizophrenia. Brain Res 2010; 1320: 130-4.
-
(2010)
Brain Res
, vol.1320
, pp. 130-134
-
-
Zhang, C.1
Xie, B.2
Fang, Y.3
-
92
-
-
4444355660
-
Folate, homocysteine, and negative symptoms in schizophrenia
-
Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004; 161: 1705-8.
-
(2004)
Am J Psychiatry
, vol.161
, pp. 1705-1708
-
-
Goff, D.C.1
Bottiglieri, T.2
Arning, E.3
-
93
-
-
84874528259
-
Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia
-
Roffman JL, Brohawn DG, Nitenson AZ, et al. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 2013; 39: 330-8.
-
(2013)
Schizophr Bull
, vol.39
, pp. 330-338
-
-
Roffman, J.L.1
Brohawn, D.G.2
Nitenson, A.Z.3
-
94
-
-
56249097252
-
MTHFR 677C - > T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val - > Met
-
Roffman JL, Gollub RL, Calhoun VD, et al. MTHFR 677C - > T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val - > Met. Proc Natl Acad Sci USA 2008; 105: 17573-8.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 17573-17578
-
-
Roffman, J.L.1
Gollub, R.L.2
Calhoun, V.D.3
-
95
-
-
79952316920
-
Folate supplementation in schizophrenia: A possible role for MTHFR genotype
-
Hill M, Shannahan K, Jasinski S, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 2011; 127: 41-5.
-
(2011)
Schizophr Res
, vol.127
, pp. 41-45
-
-
Hill, M.1
Shannahan, K.2
Jasinski, S.3
-
96
-
-
84878567704
-
A multicenter investigation of folate plus B12 supplementation in schizophrenia
-
in press
-
Roffman JL, Lamberti JS, Achtyes E, et al. A multicenter investigation of folate plus B12 supplementation in schizophrenia. Arch Gen Psychiatry (in press).
-
Arch Gen Psychiatry
-
-
Roffman, J.L.1
Lamberti, J.S.2
Achtyes, E.3
-
97
-
-
0036787407
-
Elevated homocysteine levels in young male patients with schizophrenia
-
Levine J, Stahl Z, Sela BA, et al. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 2002; 159: 1790-2.
-
(2002)
Am J Psychiatry
, vol.159
, pp. 1790-1792
-
-
Levine, J.1
Stahl, Z.2
Sela, B.A.3
-
98
-
-
0037364417
-
Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders
-
Mattson MP, Shea TB,. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26: 137-46.
-
(2003)
Trends Neurosci
, vol.26
, pp. 137-146
-
-
Mattson, M.P.1
Shea, T.B.2
-
99
-
-
0035798238
-
The molecular biology of memory storage: A dialogue between genes and synapses
-
Kandel ER,. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001; 294: 1030-8.
-
(2001)
Science
, vol.294
, pp. 1030-1038
-
-
Kandel, E.R.1
-
100
-
-
84870606869
-
A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples
-
Roussos P, Katsel P, Davis KL, et al. A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Arch Gen Psychiatry 2012; 69: 1205-13.
-
(2012)
Arch Gen Psychiatry
, vol.69
, pp. 1205-1213
-
-
Roussos, P.1
Katsel, P.2
Davis, K.L.3
-
101
-
-
3142661662
-
Animal models of working memory: Insights for targeting cognitive dysfunction in schizophrenia
-
Castner SA, Goldman-Rakic PS, Williams GV,. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 2004; 174: 111-25.
-
(2004)
Psychopharmacology
, vol.174
, pp. 111-125
-
-
Castner, S.A.1
Goldman-Rakic, P.S.2
Williams, G.V.3
-
102
-
-
21844469260
-
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers
-
Barch DM, Carter CS,. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 2005; 77: 43-58.
-
(2005)
Schizophr Res
, vol.77
, pp. 43-58
-
-
Barch, D.M.1
Carter, C.S.2
-
103
-
-
34247387212
-
Tolcapone improves cognition and cortical information processing in normal human subjects
-
Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007; 32: 1011-20.
-
(2007)
Neuropsychopharmacology
, vol.32
, pp. 1011-1020
-
-
Apud, J.A.1
Mattay, V.2
Chen, J.3
-
104
-
-
34249319444
-
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
-
George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007; 93: 42-50.
-
(2007)
Schizophr Res
, vol.93
, pp. 42-50
-
-
George, M.S.1
Molnar, C.E.2
Grenesko, E.L.3
-
105
-
-
0025952455
-
Recent advances in the phencyclidine model of schizophrenia
-
Javitt D, Zukin S,. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
-
(1991)
Am J Psychiatry
, vol.148
, pp. 1301-1308
-
-
Javitt, D.1
Zukin, S.2
-
106
-
-
0028323167
-
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
-
Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
-
(1994)
Arch Gen Psychiatry
, vol.51
, pp. 199-214
-
-
Krystal, J.H.1
Karper, L.P.2
Seibyl, J.P.3
-
107
-
-
9244243064
-
Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis
-
Tuominen HJ, Tiihonen J, Wahlbeck K,. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005; 72: 225-34.
-
(2005)
Schizophr Res
, vol.72
, pp. 225-234
-
-
Tuominen, H.J.1
Tiihonen, J.2
Wahlbeck, K.3
-
108
-
-
35748969317
-
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
-
Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-602.
-
(2007)
Am J Psychiatry
, vol.164
, pp. 1593-1602
-
-
Buchanan, R.W.1
Javitt, D.C.2
Marder, S.R.3
-
110
-
-
0033557737
-
A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia
-
Goff D, Henderson D, Evins A, et al. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512-4.
-
(1999)
Biol Psychiatry
, vol.45
, pp. 512-514
-
-
Goff, D.1
Henderson, D.2
Evins, A.3
-
111
-
-
0029853426
-
D-cycloserine added to clozapine for patients with schizophrenia
-
Goff DC, Tsai G, Manoach DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628-30.
-
(1996)
Am J Psychiatry
, vol.153
, pp. 1628-1630
-
-
Goff, D.C.1
Tsai, G.2
Manoach, D.S.3
-
112
-
-
1542617755
-
Glycine transporter i inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
-
Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
-
(2004)
Biol Psychiatry
, vol.55
, pp. 452-456
-
-
Tsai, G.1
Lane, H.Y.2
Yang, P.3
-
113
-
-
77955056793
-
High dose D-serine in the treatment of schizophrenia
-
Kantrowitz JT, Malhotra D, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125-30.
-
(2010)
Schizophr Res
, vol.121
, pp. 125-130
-
-
Kantrowitz, J.T.1
Malhotra, D.2
Cornblatt, B.3
-
114
-
-
0034898096
-
Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine
-
Sheinin A, Shavit S, Benveniste M,. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 2001; 41: 151-8.
-
(2001)
Neuropharmacology
, vol.41
, pp. 151-158
-
-
Sheinin, A.1
Shavit, S.2
Benveniste, M.3
-
115
-
-
84866703056
-
D-cycloserine: An evolving role in learning and neuroplasticity in schizophrenia
-
Goff DC,. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 2012; 38: 936-41.
-
(2012)
Schizophr Bull
, vol.38
, pp. 936-941
-
-
Goff, D.C.1
-
116
-
-
79955474438
-
Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory
-
Hillman BG, Gupta SC, Stairs DJ, et al. Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol Learn Mem 2011; 95: 404-14.
-
(2011)
Neurobiol Learn Mem
, vol.95
, pp. 404-414
-
-
Hillman, B.G.1
Gupta, S.C.2
Stairs, D.J.3
-
117
-
-
77953604398
-
Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting
-
Zhang Y, Llinas RR, Lisman JE,. Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Front Neural Circuits 2009; 3: 20.
-
(2009)
Front Neural Circuits
, vol.3
, pp. 20
-
-
Zhang, Y.1
Llinas, R.R.2
Lisman, J.E.3
-
118
-
-
16844387460
-
Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats
-
Parnas AS, Weber M, Richardson R,. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005; 83: 224-31.
-
(2005)
Neurobiol Learn Mem
, vol.83
, pp. 224-231
-
-
Parnas, A.S.1
Weber, M.2
Richardson, R.3
-
119
-
-
56049099989
-
Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
-
Goff DC, Cather C, Gottlieb JD, et al. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320-7.
-
(2008)
Schizophr Res
, vol.106
, pp. 320-327
-
-
Goff, D.C.1
Cather, C.2
Gottlieb, J.D.3
-
120
-
-
80051781845
-
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
-
Gottlieb JD, Cather C, Shanahan M, et al. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res 2011; 131: 69-74.
-
(2011)
Schizophr Res
, vol.131
, pp. 69-74
-
-
Gottlieb, J.D.1
Cather, C.2
Shanahan, M.3
-
121
-
-
44349151445
-
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
-
Norberg MM, Krystal JH, Tolin DF,. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118-26.
-
(2008)
Biol Psychiatry
, vol.63
, pp. 1118-1126
-
-
Norberg, M.M.1
Krystal, J.H.2
Tolin, D.F.3
|